山西女首富，接任350亿医美巨头总经理，公司刚获钟睒睒20亿押注

Core Viewpoint - The article discusses significant changes in the governance structure of Jinbo Bio, following the announcement of a 2 billion yuan fundraising plan involving Zhong Shanshan's company, indicating a strategic partnership and operational adjustments within the company [1][9]. Company Overview - Jinbo Bio focuses on the research, production, and application of recombinant humanized collagen, with products spanning medical devices, functional skincare, and antiviral fields [1]. - As of the latest market close, Jinbo Bio's market capitalization stands at 36 billion yuan [2]. Management Changes - On September 8, the company announced that founder and actual controller Yang Xia has resumed the role of General Manager, overseeing company operations [4]. - The previous General Manager, Jin Xuekun, will continue to manage growth sectors, including medical aesthetics and international business, ensuring strategic continuity [4]. - Yang Xia, born in 1974, has been deeply involved in the company's development since 2008 and has held various leadership roles, including Chairman and head of the research institute [4]. Financial Performance - In the first half of 2025, Jinbo Bio reported revenue of 859 million yuan, a year-on-year increase of 42.43%, and a net profit attributable to shareholders of 392 million yuan, up 26.65% [7]. - Sales expenses surged to 181 million yuan, reflecting a 67.77% increase compared to the same period last year, primarily due to higher personnel costs and increased brand promotion investments [7]. Strategic Partnerships - The management changes coincide with a significant capital increase plan, where Jinbo Bio intends to issue shares to Zhong Shanshan's YS Group, raising a total of 2 billion yuan [9]. - Following the completion of the share issuance, Zhong Shanshan's entities will hold a combined 10.58% stake in Jinbo Bio, making them the second-largest shareholder [9]. - This partnership is seen as a strategic move to enhance decision-making efficiency and operational capabilities within Jinbo Bio [7][9]. Market Context - The recombinant collagen market in China is experiencing rapid growth, with penetration rates increasing from 16% to 37.7% [9]. - Jinbo Bio faces competitive pressures from industry giants and must navigate challenges related to production capacity and market expansion [10]. - The company aims to leverage its partnership with YS Group to explore applications of collagen in serious medical fields, addressing the over-reliance on aesthetic products [13].